The Efficacy and Safety of Intravenous Prostaglandin E1 in the Management of Retinal Artery Occlusion: A Systematic Review.

IF 2.3 2区医学 Q2 OPHTHALMOLOGY

Retina-The Journal of Retinal and Vitreous Diseases Pub Date : 2025-03-05 DOI:10.1097/IAE.0000000000004458

Hashem Abu Serhan, Ahmed Oweidah, Abdulla Shaheen, Laith O Emoush, Abdullah Bin Mahmoud, Mutaz Al-Nawaflh, Ayman G Elnahry

{"title":"The Efficacy and Safety of Intravenous Prostaglandin E1 in the Management of Retinal Artery Occlusion: A Systematic Review.","authors":"Hashem Abu Serhan, Ahmed Oweidah, Abdulla Shaheen, Laith O Emoush, Abdullah Bin Mahmoud, Mutaz Al-Nawaflh, Ayman G Elnahry","doi":"10.1097/IAE.0000000000004458","DOIUrl":null,"url":null,"abstract":"Purpose: To evaluate the efficacy and safety of prostaglandin E1 (PGE1) for the management of central/branch retinal artery occlusion (CRAO/BRAO).Methods: Our protocol was registered prospectively on PROSPERO (CRD42024522961). We searched 4 electronic databases [PubMed, Scopus, Web of Science, and Google Scholar] to retrieve all studies reported using PGE1 for patients with CRAO/BRAO. We conducted a Wilcoxon signed-rank test to assess the effect of PGE1 on the visual acuity (VA) of included subjects. VA change was utilized as a measure to assess the degree of VA improvement. We assessed the quality of included studies using the JBI tool.Results: We included a total of 6 studies with a total of 21 cases. Age ranged from 45 to 97 years with a mean of 65.76 years for 10 females and 11 males. Cases with CRAO represented 85.7% and BRAO represented 14.3% of total cases. The median time from symptoms onset to treatment initiation was 7 hours. The median for the initial dose was 40 μg. Wilcoxon signed-rank test revealed significant improvement in visual acuity after intravenous PGE1 treatment (V = 231, p < 0.05).Conclusion: Our analysis revealed preliminary evidence suggesting that IV PGE1 may be a potentially safe and effective treatment for improving VA in patients with CRAO/BRAO. However, our evidence is limited as our review relies primarily on case reports and case series.","PeriodicalId":54486,"journal":{"name":"Retina-The Journal of Retinal and Vitreous Diseases","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Retina-The Journal of Retinal and Vitreous Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/IAE.0000000000004458","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To evaluate the efficacy and safety of prostaglandin E1 (PGE1) for the management of central/branch retinal artery occlusion (CRAO/BRAO).

Methods: Our protocol was registered prospectively on PROSPERO (CRD42024522961). We searched 4 electronic databases [PubMed, Scopus, Web of Science, and Google Scholar] to retrieve all studies reported using PGE1 for patients with CRAO/BRAO. We conducted a Wilcoxon signed-rank test to assess the effect of PGE1 on the visual acuity (VA) of included subjects. VA change was utilized as a measure to assess the degree of VA improvement. We assessed the quality of included studies using the JBI tool.

Results: We included a total of 6 studies with a total of 21 cases. Age ranged from 45 to 97 years with a mean of 65.76 years for 10 females and 11 males. Cases with CRAO represented 85.7% and BRAO represented 14.3% of total cases. The median time from symptoms onset to treatment initiation was 7 hours. The median for the initial dose was 40 μg. Wilcoxon signed-rank test revealed significant improvement in visual acuity after intravenous PGE1 treatment (V = 231, p < 0.05).

Conclusion: Our analysis revealed preliminary evidence suggesting that IV PGE1 may be a potentially safe and effective treatment for improving VA in patients with CRAO/BRAO. However, our evidence is limited as our review relies primarily on case reports and case series.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Retina-The Journal of Retinal and Vitreous Diseases 医学-眼科学

CiteScore

5.70

自引率

9.10%

发文量

554

审稿时长

3-6 weeks

期刊介绍： RETINA® focuses exclusively on the growing specialty of vitreoretinal disorders. The Journal provides current information on diagnostic and therapeutic techniques. Its highly specialized and informative, peer-reviewed articles are easily applicable to clinical practice. In addition to regular reports from clinical and basic science investigators, RETINA® publishes special features including periodic review articles on pertinent topics, special articles dealing with surgical and other therapeutic techniques, and abstract cards. Issues are abundantly illustrated in vivid full color. Published 12 times per year, RETINA® is truly a “must have” publication for anyone connected to this field.